Skip to main content
TipRanks
Go Ultimate75% OFF

Ryvu Therapeutics SA (0RKT) Share Price & Analysis

0 Followers

0RKT Stock Chart & Stats

zł 30.25zł 0.00(0.00%)
At close: 4:30 PM GMT
zł 30zł 30.25zł 30.5Jun 4Jun 6Jun 10
Day’s Range
PLN 30.25 - PLN 30.25
52-Week Range
PLN 30.25 - PLN 30.25
Previous Close
PLN 30.25
Volume
N/A
Average Volume (3M)
0
Market Cap
PLN 390.27M
Enterprise Value
PLN 381.76M
Total Cash (Recent Filing)
PLN 57.55M
Total Debt (Recent Filing)
PLN 77.72M
Price to Earnings (P/E)
―
Beta
0.86
Next Earnings
Mar 16, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

The company's strong revenue growth rate indicates expanding operations and potential market capture, which is crucial for long-term sustainability in the competitive biotech industry.

Gross Profit Margin

A strong gross profit margin suggests effective cost management and pricing power, which can support future profitability as the company scales its operations.

Cash Flow Growth

Positive free cash flow growth indicates improving cash generation ability, which is essential for funding R&D and supporting strategic initiatives without relying heavily on external financing.

Bears Say

Profitability Challenges

Ongoing profitability issues highlight difficulties in converting revenue into net income, which could hinder long-term financial health and investment in growth opportunities.

Operating Cash Flow

Negative operating cash flow suggests the company is not generating sufficient cash from its core operations, potentially limiting its ability to sustain growth and meet financial obligations.

Return On Equity

Negative return on equity reflects inefficiencies in using shareholder funds to generate profits, which could deter investors and affect the company's ability to raise capital.

0RKT FAQ

What was Ryvu Therapeutics SA’s price range in the past 12 months?
Ryvu Therapeutics SA lowest share price was zł 30.25 and its highest was zł 30.25 in the past 12 months.
What is Ryvu Therapeutics SA’s market cap?
Ryvu Therapeutics SA’s market cap is zł 390.27M.
When is Ryvu Therapeutics SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Ryvu Therapeutics SA’s earnings last quarter?
Ryvu Therapeutics SA released its earnings results on Nov 05, 2026. The company reported -zł 0.824 earnings per share for the quarter.
Is Ryvu Therapeutics SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Ryvu Therapeutics SA pay dividends?
Ryvu Therapeutics SA does not currently pay dividends.
What is Ryvu Therapeutics SA’s EPS estimate?
Ryvu Therapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ryvu Therapeutics SA have?
Ryvu Therapeutics SA has 23,120,148 shares outstanding.
What happened to Ryvu Therapeutics SA’s price movement after its last earnings report?
Ryvu Therapeutics SA reported an EPS of -zł 0.824 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ryvu Therapeutics SA?
Currently, no hedge funds are holding shares in GB:0RKT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology